Products for Research Use Only

A 83-01 (Standard)

CAT: 0804-HY-10432R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10432R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
A 83-01 (Standard) is the analytical standard of A 83-01. This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively[1].
CAS Number
909910-43-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Reference Standards; TGF-β Receptor
Related Pathways
Others; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.69
Smiles
S=C(N1N=C(C(C2=C3C=CC=CC3=NC=C2)=C1)C4=CC=CC(C)=N4)NC5=CC=CC=C5
Molecular Formula
C25H19N5S
Molecular Weight
421.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96 (11) :791-800.|[2]Yamamura S, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012 Jan 1;130 (1) :20-8. |[3]Taniguchi Y, et al. Enhanced antitumor efficacy of folate-linked liposomal Adriamycin with TGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101 (10) :2207-13.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, sealed storage, away from light and moisture, under nitrogen
Scientific Category
Reference Standards
Clinical Information
No Development Reported
Isoform
ALK4; ALK5; ALK7